RxDoctor Payments Data

Albert Min, MD

Hepatology · New York, NYNPI 1396720256

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $221,507 of the $276,932 with a category attached, or 80.0%. Gilead accounts for 61.4% of it on its own, with 10 other manufacturers making up the rest.

$276,932in general payments, 2019–2025

Across 364 payments — averaging $760.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$170K
  • Madrigal Pharmaceuticals$47K
  • AbbVie$40K
  • Intercept Pharmaceuticals, Inc.$12K
  • GSK$3K
  • Novo Nordisk$3K
  • plus $2K from 5 others
$6,994in research payments, 2019–2025

Across 1 payment — averaging $6993.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$7K

What the payments were for

  • Consulting fees$21,1008%
  • Speaking & faculty fees$221,50780%
  • Travel & lodging$24,7069%
  • Food & beverage$9,5013%
  • Education$1190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$276,932 in reported general payments places this provider in the 85th percentile of 29 hepatology providers in New York.

See all hepatology providers in New York

Medicare billing

Part B allowed, 2024
$81,079
Medicare patients
313
Services billed
782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VemlidyTenofovir Alafenamide139$224,246
XifaxanRifaximin23$74,928
RezdiffraResmetirom13$49,025
Entecavir60$17,728
Ursodiol55$8,615
Tacrolimus13$3,700
Tenofovir Disoproxil Fumarate12$3,375
Lactulose42$1,209
Nadolol17$659
Famotidine39$397
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl28$356
Pantoprazole Sodium39$342
EnuloseLactulose19$172
Spironolactone11$145
Omeprazole25$132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$170,060$224,246139 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$48$74,92823 claims
Madrigal PharmaceuticalsRezdiffra$47,107$49,02513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 29 hepatology providers in New York.

Other hepatology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →